AZN - AstraZeneca PLC
| Previous Close | 38.87 |
| Open | 38.49 |
| Bid | 36.86 x 800 |
| Ask | 41.00 x 3000 |
| Day's Range | 38.12 - 38.71 |
| 52 Week Range | 32.69 - 41.78 |
| Volume | 3,825,914 |
| Avg. Volume | 4,541,055 |
| Market Cap | 95.752B |
| Beta (3Y Monthly) | 0.64 |
| PE Ratio (TTM) | 39.98 |
| EPS (TTM) | 0.95 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.43%) |
| Ex-Dividend Date | 2018-08-09 |
| 1y Target Est | 42.26 |
- Insider Monkey•23 hours ago
Is Bristol Myers Squibb Co. (BMY) A Good Stock To Buy According To Hedge Funds?
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Bloomberg•2 days agoNew Biotech IPO Dropped a Unicorn-Sized Value on Its First Day
The $1.4 billion Moderna lost in value is greater than the market value of more than half the companies in the Nasdaq Biotechnology Index. The company boasts partnerships with sector juggernauts including Merck & Co. and AstraZeneca Plc, so its growth prospects have attracted notable attention across the sector.
- Reuters•3 days ago
AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study
The results come after AstraZeneca warned last month that its immunotherapy treatment Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares. AstraZeneca has been seen as having a head start in the race for cancer treatments, and Imfinzi was aiming to be the new standard of care in treating early inoperable stage III lung cancer.
Motley Fool•4 days agoHere's Why Agenus Stock Popped 51.6% in November
One big drugmaker's pain was this biotech's gain last month.
- Zacks•4 days ago
Inovio (INO) to Receive Milestone Payment From AstraZeneca
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
- Moody's•4 days ago
GlaxoSmithKline Capital Inc. -- Moody's changes GSK's outlook to negative; affirms A2 ratings
Moody's Investors Service has today changed to negative from stable the outlook of GlaxoSmithKline plc (GSK) and its guaranteed subsidiaries. The change in outlook follows the company's 3 December announcement of its intention to acquire Tesaro for $5.1 billion. At the same time, Moody's has affirmed GSK's A2/(P)A2 long-term and (P)Prime-1 ratings.
- ACCESSWIRE•4 days ago
Today's Research Reports on Trending Tickers: Eli Lilly and Company and AstraZeneca
NEW YORK, NY / ACCESSWIRE / December 5, 2018 / U.S. equities plunged on Tuesday as skepticism over the U.S. and China’s ability to close a trade agreement weighed on the markets. The Dow Jones Industrial ...
- Financial Times•5 days ago
[$$] ‘Repeat offender’ companies warned of fresh investor onslaught
, have been warned they face fresh shareholder unrest if they fail to address investor concerns that have already resulted in significant protest votes at their annual meetings. The Investment Association has written to 32 companies that appeared on the UK trade body’s Public Register of shareholder votes for the past two years. The “repeat offenders” landed on the register for the “exact same resolution” in consecutive years, suggesting they had not responded “sufficiently to investor views and in doing so are risking more shareholder dissent”.
- Zacks•5 days ago
Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%
Glaxo (GSK) announces definitive deal to buy TESARO.
- Zacks•5 days ago
TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer
TESARO (TSRO) receives an acquisition offer from London-based pharma giant, Glaxo, valuing the company at $75 a share. Total value of the deal stands at $5.1 billion which includes acquisition of debt.
- Business Wire•6 days ago
New Long-Term Data on CALQUENCE Presented at ASH 2018
26 months median duration of response achieved in relapsed or refractory mantle cell lymphoma at updated two-year analysis
- Investor's Business Daily•10 days ago
Moderna IPO On Path To Be Largest Offering Of Venture-Backed Biotech
The Moderna IPO is set to become the largest public debut of a venture capital-backed biotech company, after it announced terms that could raise $521 million.
- Reuters•11 days ago
Biocartis partners with AstraZeneca on lung cancer diagnostics
Following the agreement, a prospective lung cancer study with Biocartis's Idylla EGFR Mutation Test will be conducted in Belgium, France, Germany and Italy. "We are very excited to be collaborating with AstraZeneca in the area of lung cancer ... For Biocartis, this is yet another important collaboration to support the further roll-out of our Idylla platform," Biocartis Chief Executive Officer Herman Verrelst said.
- Simply Wall St.•11 days ago
AstraZeneca PLC (LON:AZN): The Best Of Both Worlds
Attractive stocks have exceptional fundamentals. In the case of AstraZeneca PLC (LON:AZN), there’s is a company with a an impressive history of dividend payments as well as a excellent future Read More...
- GlobeNewswire•11 days ago
Biocartis Group NV: Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results
PRESS RELEASE : 29 November 2018, 07:00 CET Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results Mechelen, Belgium, 29 November 2018 - Biocartis Group NV (the ...
- Motley Fool•11 days ago
3 Top Dividend Stocks to Buy Right Now
These income-generating businesses deserve a place in your portfolio.
- The Wall Street Journal•12 days ago
[$$] Drugmakers Gain More Access to China, but at a Price
China is approving foreign drugs at a record pace, opening the door to its lucrative market for the world’s leading pharmaceutical companies, while also extracting big discounts. Regulators have greenlighted dozens of outside drugs for use in China over the past 21 months, some within a few weeks. The approvals follow a series of policy moves by China to provide its 1.4 billion people access to new, lifesaving drugs, especially those that treat cancer.
- Zacks•12 days ago
Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease
AstraZeneca (AZN) gets Orphan Drug status for Fasenra in the United States for the treatment of eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease.
- Business Wire•12 days ago
AstraZeneca Presents Clinical Research Advances for Blood Cancer Patients at 2018 American Society of Hematology Annual Meeting
27 scientific presentations, including long-term data from CALQUENCE in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic leukemia
- Zacks•13 days ago
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
- Zacks•16 days ago
Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs
FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs
- Simply Wall St.•16 days ago
Read This Before You Buy AstraZeneca PLC (LON:AZN) Because Of Its P/E Ratio
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we’ll show how AstraZeneca PLC’s (LON:AZN) P/E Read More...
